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Abstract
Background: Esophageal squamous cell carcinomas (ESCCs) are often accompanied by head and neck second primary
tumors (HNSPTs). The prognosis of patients with an additional HNSPT is worse compared with patients with only ESCC.
Therefore, early detection of HNSPTs may improve the overall outcome of patients with ESCC.
The purpose of this study was to investigate the yield of endoscopic screening for HNSPTs in patients with primary ESCC.
Methods: We conducted a systematic literature search of all available databases. Studies were included if ESCC patients
were endoscopically screened for HNSPT. The primary outcome was the pooled prevalence of HNSPTs.
Results: Twelve studies, all performed in Japan, were included in this systematic review with a total of 6483 patients.
The pooled prevalence of HNSPTs was 6.7% (95% confidence interval: 4.9–8.4). The overall heterogeneity was high
across the studies (I2¼ 89.0%, p< 0.001). Most HNSPTs were low stage (85.3%) and located in the hypopharynx
(60.3%). The proportion of synchronous (48.2%) and metachronous (51.8%) HNSPTs was comparable.
Conclusion: Based on our results, HNSPT screening could be considered in patients with primary ESCC. All studies were
performed in Japan; it is therefore not clear whether this consideration applies to the Western world.
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Key summary
. The prognosis of patients with esophageal squamous cell carcinoma (ESCC) and an additional head and
neck second primary tumor (HNSPT) is worse than patients with only ESCC. Early detection of HNSPT
may improve patient outcome.
. The pooled prevalence of HNSPT in patients with ESCC is 6.7%.
. Most HNSPTs are low stage (85.3%) and located in the hypopharynx (60.3%).
. HNSPT screening could be considered in patients with primary ESCC.
. Western screening studies are needed, since all studies have been performed in Japan.
Introduction
Both esophageal and head and neck (HN) cancer are
common malignancies worldwide.1,2 Esophageal squa-
mous cell carcinoma (ESCC) is the most common
histologic type in the esophagus.3 Patients with ESCC
frequently develop second primary tumors (SPTs) in
the upper aerodigestive tract, most often in the HN
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region, but also in the esophagus and lungs.4,5 The
presence of SPTs can be explained by the ‘‘ﬁeld cancer-
ization’’ theory: Premalignant epithelial changes can
occur because of chronic local exposure to common
carcinogens, such as alcohol and tobacco, which con-
tributes to the development of syn- and metachronous
SPTs.6 An important risk factor in Western countries
for the development both of ESCC and SPTs
is alcohol.7,8
Head and neck second primary tumors (HNSPTs) in
patients with primary ESCC are reported to be up
to 7% in retrospective studies.4,5 The prognosis and
survival of patients with esophageal cancer (EC) is
poor because most ECs are diagnosed in advanced
stages, when deﬁnitive cure is most often not achiev-
able.9 The long-term prognosis is even worse in patients
with an additional HNSPT compared with ESCC alone
(ﬁve-year survival rate of 9.2% vs 21.0%).10 This poor
prognosis makes early detection of HNSPTs vitally
important, especially for ESCC patients with low-
stage tumors that could be treated endoscopically,
since they have a considerably higher ﬁve-year
survival rate.11
Diﬀerent endoscopic techniques for HN cancer
screening have been studied. Although Lugol
chromoendoscopy is often used in the esophagus to
detect dysplastic mucosal lesions, it is known to
cause side eﬀects in the HN region such as chest
pain and aspiration.12 Narrow-band imaging (NBI)
seems to be the best technique for the detection of
HNSPTs in patients with primary ESCC.13 The
HNSPT detection rate is signiﬁcantly higher using
NBI (sensitivity 100%, speciﬁcity 97.5%) compared
with only white-light endoscopy (WL).13 The sensitivity
of ﬂuorodeoxyglucose–positron-emission tomography/
computed tomography (CT) for the detection of
HNSPTs is 61.5%; more HNSPTs have been detected
by endoscopy.14
The European Society for Medical Oncology
Clinical Practice Guidelines for EC recommends endo-
scopic screening of the HN region and trachea-
bronchoscopy to detect SPTs in the upper aerodigestive
tract in all ESCC patients with chronic tobacco and
alcohol consumption.15 However, no Western screening
studies have been published to date. The Japanese EC
guidelines recommend appropriate diagnostic measures
of other organs (HN, stomach, large intestine) after
treatment of ESCC because of the risk of developing
SPTs.16 However, no speciﬁc screening recommenda-
tions (i.e. diagnostic method and time of screening)
are mentioned.16
We have performed a systematic review and meta-
analysis of studies that investigated the use of endo-
scopic screening for the detection of HNSPTs in
patients with primary ESCC. Our primary objective
was to investigate the yield of endoscopic screening
for HNSPTs in patients with primary ESCC.
Our secondary objectives were to investigate whether
there is evidence to justify endoscopic HN screening
in primary ESCC patients in the Western world, and
to investigate whether screening should be performed
synchronously or metachronously.
Materials and methods
Literature search and selection criteria
A systematic literature search was performed in collab-
oration with the medical library of the Erasmus
University Rotterdam, the Netherlands, in February
2019, with no limit on publication date. The search
was performed in PubMed, Embase, Medline,
Cochrane Central, Google Scholar and Web of
Science databases. The full electronic search strategy
for the Embase database is provided in
Supplementary Appendix 1. The search was limited to
English studies performed on humans. After removing
duplicate citations, the remaining articles were reviewed
based on title and abstract by two independent
reviewers (S.E.M.V. and O.B.). Subsequently, the full
text of the remaining articles was screened by the same
authors and discrepancies were discussed mutually. If
there was no agreement, a third party was involved
(A.D.K.). Studies were included if patients with pri-
mary ESCC were endoscopically screened for
HNSPTs. Studies were excluded if patients with pri-
mary head and neck squamous cell carcinoma
(HNSCC) were screened for esophageal SPTs, since
we investigated the yield of HNSPT screening in
patients with primary ESCC. Moreover, these studies
are already included in a systematic review about
screening for esophageal SPT in patients with primary
HNSCC.17 Studies without full text, case reports,
reviews, and studies in which only imaging techniques
were used to detect HNSPTs were excluded. References
of the retrieved studies were manually screened to
locate additional studies.
Study quality
The Methodological Index for Non-Randomized
Studies (MINORS) was used to test the risk of bias
and the methodological quality of the selected studies.18
The study relevance was determined using a checklist.
This checklist includes (1) the impact factor of the pub-
lishing journal (indication of peer-review quality), (2)
data of the HNSPT sublocation and (3) text clarity
(Table 1). The total quality score of the studies was
the sum of the MINORS and relevance criteria score.
The total scores were classiﬁed as low (10 points),
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medium (11–14 points) or high (15 points). Studies
classiﬁed as medium and high were included.
Data extraction and outcome parameters
Data from included studies were summarized as a
Preferred Reporting Items for Systematic Reviews
and Meta-Analyses checklist and ﬂowchart.19 The pri-
mary outcome was the prevalence of diagnosed
HNSPTs. An HNSPT was deﬁned as a lesion in the
HN region classiﬁed as carcinoma in situ or carcinoma.
With NBI, these lesions can be described as well-
demarcated brownish areas without magniﬁcation,
irregular microvascular patterns, and increased intrae-
pithelial papillary capillary loops.20 Secondary out-
comes were recorded when possible: (1) HNSPT
prevalence per sublocation (upper, middle and lower
esophagus) and per tumor stage (0 to IV according to
the Vienna classiﬁcation of gastrointestinal epithelial
neoplasia) of the primary ESCC, (2) synchronously
(6 months after diagnosis of primary ESCC) or meta-
chronously (>6 months after diagnosis of primary
ESCC) diagnosed HNSPTs and (3) tumor stage and sub-
location of HNSPTs.21 Other characteristics of the stu-
dies were also recorded: ﬁrst author, publication year,
study design, size and country of the study population.
Statistical analysis
For each study, the HNSPT prevalence was calculated
(total number of HNSPTs divided by the total popu-
lation that was screened). The standard error (SE) was
calculated from the prevalence using the following for-
mula: SE ¼ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃðp ð1 pÞÞ=np , p¼ prevalence and
n¼ total number of patients with ESCC that were
screened. Estimation of the prevalence was carried
out with the aid of a random-eﬀects meta-analysis.
Combined estimates and 95% conﬁdence intervals
(CIs) for the HNSPT prevalence rates were calculated.
The heterogeneity among studies was measured by
calculating the inconsistency index (I2), with values
from 0% to 100% (maximum heterogeneity).
Categories of low, moderate and high were assigned
to I2 values of 25%, 50% and 75%, respectively.22
When I2 50%, there was evidence of moderate or
high heterogeneity.
Results
Study selection and quality assessment
The study selection process and eligibility assessment
are outlined in Figure 1. The literature search identiﬁed
4537 citations. After screening, 148 articles were exam-
ined by full-text review for their eligibility by two
reviewers (S.E.M.V. and O.B.). Discrepancies were dis-
cussed mutually without any ﬁnal disagreements. One
additional study was included after screening the refer-
ences. Twelve studies were included in our systematic
review.7,10,13,20,23–30 Exclusion reasons are shown in
4537
1998 Embase
Medline
Web of Science
Cochrane central
Google scholar
duplicates
title/ abstract screening
2532 records screened
after duplicates removed
148 full-text articles
assessed for eligibility
58 incidence
7 screening for EC in HN
6 review/ guideline
13 risk factor/ treatment
6 genetics/ biomarkers
11 case reports
11 imaging
2 no EC group
7 no HN group
11 no full text
Study criteria
16 eligible endoscopic
screening studies
11 screening studies
included
1 cross reference
included
12 screening studies
included
2005 excluded
2384 excluded
132 excluded
5 excluded
1173
1129
37
200
records identified
database screening
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Figure 1. Study selection process.
EC: esophageal cancer; HN: head and neck cancer.
Table 1. Relevance criteria.
Score
Criteria 0 1 2
Text clarity Low Medium High
Sublocation No – Yes
Impact factor <2 2–3.9 4
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Figure 1. All 12 included studies qualiﬁed as medium or
high (Table 2). The relevance criteria score ranged
between 0 and 5 points (maximum possible score is
6). The MINORS criteria score ranged from 9 to 23
points (maximum possible score of 24).
Study characteristics
The study characteristics are reported in Table 2. All
studies were performed in Japan and published between
2002 and 2018. Nine of the 12 studies (75%) collected
their data prospectively7,10,13,20,24,25,27,28,30 and three
(25%) retrospectively.23,26,29 The total number
of included patients was 6483 (median, 313; range,
71–1674). In two studies Lugol iodine was used for
screening of the HN region.24,28 In ﬁve other studies
both WL and NBI were used for screening.13,20,23,26,30
In the remaining ﬁve studies, only WL was used for
screening.7,10,25,27,29 In only four studies, the entire
HN region was screened.10,20,27,28,30 Screening was
limited to the pharynx and larynx, sublocations
known to be at an increased risk, in most other studies.
Eleven of the 12 studies screened only patients with
ESCC.7,10,13,20,23–26,28–30 One study screened patients
with both ESCC (93%) and esophageal adenocarcin-
oma (7%).27 In total, 98% of the esophageal tumors
were squamous cell carcinomas and 2% adenocarcin-
omas. Screening was performed by an otolaryngologist
or head and neck surgeon in 5/12 included stu-
dies.7,24,25,27,28 Screening was performed by a gastro-
enterologist in 2/12 studies.20,29 In these two studies,
only the oropharynx and hypopharynx were screened.
In 5/12 included studies, however, it was not clearly
reported who performed the screening endoscopy of
the head and neck region (otolaryngologist or
gastroenterologist).10,13,23,26,30
Pooled SPT prevalence
The prevalence of HNSPTs in patients with ESCC is
shown for each study in Figure 2. In total, 353/6483
patients were diagnosed with HNSPT. Meta-analysis
with a random-eﬀect model was used to calculate the
pooled prevalence since the I2 was 89.0%. The pooled
prevalence for HNSPTs of the 12 included studies was
6.7% (95% CI: 4.9–8.4%) (Figure 2).
Sublocation of HNSPT and tumor stage
The sublocation of the HNSPTs was reported in eight of
the 12 studies, for a total of 288 SPTs.10,13,23–26,28,30 In
one study the sublocation was reported together for pri-
mary HN tumors and HNSPTs. Therefore, we excluded
the study for this subanalysis.10 A total of 234 HNSPTs
remained. The combined data showed that 60% (141/
234) of all HNSPTs were located in the hypopharynx,
18% (41/234) in the oropharynx, 11% (26/234) in the
oral cavity, 9% (22/234) in the larynx and 2% (4/234) in
other sublocations. In total, 405 HNSPTs were detected
in 353 patients. Tumor stage of HNSPTs was reported in
eight of the 12 studies.13,20,23,24,26–28,30 Morimoto et al.
reported tumor characteristics of metachronous
Table 2. Study characteristics and quality score of all 12 studies.
AuthorsRef Year Design N Method
Quality Score
Quality Screening sitesMINORS Rel Total
Abiko et al.7 2018 Pro 158 WL 18 3 21 High Larynx
Onochi et al.29 2018 Retro 285 WL 10 3 13 Medium Oro-, hypopharynx
Morimoto et al.23 2017 Retro 307 WLþNBI 18 5 23 High Oro-, hypopharynx
Larynx
Kaneko et al.26 2013 Retro 348 WLþNBI 9 4 13 Medium Oral cavity
Katada et al.30 2012 Pro 71 WLþNBI 16 5 21 High Pharynx
Head and neck regiona
Muto et al.20 2010 Pro 320 WLþNBI 23 4 27 High Oro-, hypopharynx
Nonaka et al.13 2009 Pro 424 WLþNBI 19 5 24 High Pharynx
Lo et al.10 2008 Pro 1675 WL 18 3 21 High Head neck regiona
Watanabe et al.28 2007 Pro 1118 Lugol 10 3 13 Medium Head neck regiona
Shimizu et al.24 2003 Pro 99 Lugol 18 5 22 High Hypopharynx, larynx
Kagei et al.27 2002 Pro 1479 WL 10 2 12 Medium Head neck regiona
Motoyama et al.25 2003 Pro 200 WL 13 4 17 High Larynx
MINORS: Methodological Index for Non-Randomized Studies; NBI: narrow-band imaging; Pro: prospective; Rel: relevance; Retro: retrospective; WL: white-
light endoscopy.
aNasal cavity, oral cavity, naso-, oro-, and hypopharynx and larynx.
van de Ven et al. 1307
HNSPTs only.23 Combined data showed that tumor
stage was available for 62% of the HNSPTs (251/405).
Overall, HNSPTs were classiﬁed as low stage (stage 0, I
and II) in 85% (214/251) and high stage (stage III and
IV) in 15% (37/251).
Time to diagnosis
Eight studies performed both syn- and metachronous
endoscopic screening of the HN region,10,20,23–25,28–30
and six studies adequately reported the percentage of
detected synchronous and metachronous HNSPTs
(Table 3).10,23–25,28,29 The median time to metachronous
HNSPT diagnosis of these six studies ranged from 12 to
48 months. The time to SPT diagnosis in ESCC patients
was reported for all SPTs together in Motoyama et al.,
not separately for HNSPTs.25
Two studies performed only HN screening syn-
chronously,26,27 and two only metachronously.7,13 The
HNSPT prevalence in the study by Nonaka and col-
leagues13 was 3.3% (14/424) with a median detection
period of 27.6 months (range, 7.1–143.5) in patients
screened with NBI and 101.0 months (range, 11.0–
134.5) in patients screened with WL.
Primary ESCC tumor characteristics
Only four studies reported the sublocation of the index
esophageal tumor.10,24,25,27 One study included only
patients who underwent esophagectomy for thoracic
ESCC.25 The prevalence of HNSPTs in this study was
4.0%. The average percentages of index upper, middle
and lower ESCC of the other three studies were 17.0%,
57.7% and 25.3% respectively.10,24,27 However, they
did not report the prevalence of HNSPT per ESCC
sublocation. The tumor stage of the primary ESCC
was reported in nine studies (75%).7,10,20,23–25,27,29,30
On average, most esophageal lesions were stage 1
(29.0%) and stage 3 (29.8%). Other tumor stages
were 0 (high-grade dysplasia) (7.3%), 2 (20.2%) and
stage 4 (13.6%). The HNSPT prevalence per tumor
stage of the primary ESCC was reported in three stu-
dies, for which only superﬁcial ESCCs (stage 0 and I)
were screened.7,29,30
Discussion
To our knowledge, this is the ﬁrst systematic review on
endoscopic screening for HNSPTs in patients with pri-
mary ESCC. Worldwide, the incidence of HN cancer is
more than 550,000 cases annually.2 We found an
HNSPT (pooled) prevalence of 6.7%. Most HNSPTs
were located in the hypopharynx (60.3%) and classiﬁed
as low stage (85.3%). The proportion of synchronous
and metachronous HNSPTs was comparable.
Although the worldwide incidence cannot be compared
directly with the pooled prevalence from this meta-
analysis, the concept of endoscopic screening in
Katada et al.30
Study Prevalence (%)
29.6
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Figure 2. Forest plot of prevalence of head and neck second primary tumors in patients with esophageal squamous cell carcinoma.
CI: confidence interval; df: degree of freedom; HNSPT: head and neck second primary tumor; I2: inconsistency index; RE: random-effects.
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patients with ESCC shows promise. An increase in
early detection of HNSPTs could potentially improve
the overall survival of ESCC patients.
Screening in Western countries will possibly show a
diﬀerent HNSPT prevalence because the etiology partly
diﬀers among these continents, and ESCC and HNSCC
have a higher prevalence in Asia.3,31 The etiology of
ESCC in Asia is, besides smoking and alcohol intake,
clearly linked to a lowered fruit and vegetable intake.32
The overall incidence of HN cancer in Japan was increas-
ing, whereas the incidence in the United States was
decreasing.31,33 Since the included studies were per-
formed in Japan, it is unlikely that these results can be
applied to the contemporary Western population.
Nonscreening Asian studies have reported HNSPT
prevalence up to 7% in patients with primary ESCC.4,5
This is lower than the prevalence of the included studies
(3.0%–29.6%). This might indicate that active screen-
ing of ESCC patients increases the number of detected
HNSPTs.23 Early diagnosis and treatment of both
tumors can increase survival rate.23,34
Eighty-ﬁve percent of the HNSPTs were classiﬁed as
low stage, which is higher than in the general HN
cancer population.35 Morimoto et al. reported a
higher percentage of low-stage HNSPTs in patients
with primary ESCC who were actively screened, and
83% of these HNSPTs could be treated with endo-
scopic resection.23 Furthermore, survival was better in
ESCC patients with HNSPTs who were actively
screened.23 ESCC patients could beneﬁt from HN
screening because this could result in an increased
detection of superﬁcial HN cancer, which can be trea-
ted with curative intent.
There is a lack of standardization in HN exam-
ination protocols among the included studies because
diﬀerent screening techniques are used (WL, NBI and
Lugol). Studies that compared NBI with WL described
a signiﬁcantly higher detection rate of HNSPTs and a
higher sensitivity and accuracy when using
NBI.13,20,23,26 It would therefore be useful to always
perform HN screening with WL and NBI. Lugol
chromoendoscopy is not recommended in the HN
region because this has to be performed under general
anesthesia because of possible side eﬀects.28
The average percentage of synchronous and meta-
chronous HNSPTs of all studies together is comparable.
This could indicate that HN screening in patients with
ESCC should be performed during work-up and follow-
up. The median detection time of metachronous
HNSPTs ranged from 12 to 101 months.10,13,23,24,28
However, the optimal moment for screening during
follow-up has yet to be deﬁned.
Our systematic review showed that 78% of the
HNSPTs were located in the pharynx, which suggests
that the pharynx has the highest risk of developing
SPTs. Moreover, patients with pharyngeal cancer also
showed the highest prevalence of esophageal SPTs.17
The pharynx is the head and neck region that should
deﬁnitely be screened in patients with primary ESCC.
Although 10 of the 12 included studies performed
screening of the pharynx, only four studies screened
the whole HN region. We are aware of the fact that,
of these four studies, only two studies reported the
HNSPT sublocation.28,30 It was not possible to state
whether there was a correlation between ESCC tumor
stage and the occurrence of HNSPTs since this infor-
mation was reported in only three studies.7,29,30 In these
studies, only superﬁcial ESCCs (stage 0 and I) were
screened, which could underestimate the true HNSPT
prevalence per ESCC tumor stage.
Some potential limitations about the methodology
of the included studies need to be discussed: 1)
Diﬀerent screening techniques (i.e. WL, NBI, Lugol
chromoendoscopy) were used. The combination of
WL and NBI has the highest HNSPT detection rate;
potential HNSPTs could be missed when using only
WL; 2) one study performed screening with endoscopy
and CT scan.27 It was not clearly described which pro-
portion of HNSPTs were detected by endoscopic
screening. The proportion of HNSPTs detected by
endoscopic screening could be lower than reported; 3)
a diﬀerent deﬁnition of metachronous and synchronous
Table 3. Percentages of synchronous and metachronous HNSPT.
AuthorsRef Total SPTs
Synchronous
HNSPTs (%)
Metachronous
HNSPTs (%)
Median time to diagnosis,
months (range)
Morimoto et al.23 67 14 (21%) 53 (79%) 31 (7–107)
Shimizu et al.24 5 0 5 (100%) 37 (15–61)
Motoyama et al.25 8 0 8 (100%) Not reported
Watanabe et al.28 85 37 (44%) 48 (56%) 48 (12–103)
Onochi et al.29 32 23 (72%) 9 (28%) Not reported
Lo et al.10 54 47 (87%) 7 (13%) 12 (8–110)
Total 251 121 (48%) 130 (52%)
HNSPT: head and neck second primary tumor; SPT: second primary tumor.
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was used in three studies, whereby the comparison of
the diﬀerent studies was more diﬃcult and the propor-
tion of metachronous SPTs could be higher than
reported;7,27,28 4) only four studies screened the whole
HN region. Therefore, we could not easily determine
which HN sublocation was at increased risk of develop-
ing HNSPTs; and 5) because this meta-analysis con-
tained both prospective and retrospective data, a
signiﬁcant bias may be present.
In conclusion, the pooled prevalence of HNSPTs in
patients with primary ESCC is 6.7%. Most HNSPTs
were classiﬁed as low stage. Patients with low-stage HN
tumors can be treated curatively with an excellent prog-
nosis. Screening for HNSPTs could therefore be useful
in ESCC patients. More screening studies are needed to
investigate which type of ESCC (i.e. tumor stage and
sublocation) increases the risk of HNSPTs and to
report on risk factors associated with HNSPTs. More
important, it is necessary to perform Western screening
studies to assess the HNSPT prevalence since it is
unclear whether the results of Asian studies can be
extrapolated to the Western population. Head and
neck examination protocols should be standardized in
Japan; screening should be performed during work-up
and follow-up with WL in combination with NBI. The
pharynx is the head and neck region that should always
be screened.
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